Kerlikowske K
Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.
J Natl Cancer Inst Monogr. 1997(22):79-86. doi: 10.1093/jncimono/1997.22.79.
In randomized controlled trials, screening mammography has been shown to reduce mortality from breast cancer about 25% to 30% among women aged 50 to 69 years after only five to six years from the initiation of screening. Among women aged 40 to 49 years, trials have reported no reduction in breast cancer mortality after seven to nine years from the initiation of screening; after 10 to 14 years there is a 16% reduction in breast cancer mortality. Given that the incidence of breast cancer for women aged 40 to 49 years is lower and the potential benefit from mammography screening smaller and delayed, the absolute number of deaths prevented by screening women aged 40 to 49 years is much less than in screening women aged 50 to 69 years. Because the absolute benefit of screening women aged 40 to 49 years is small and there is concern that the harms are substantial, the focus should be to help these women make informed decisions about screening mammography by educating them of their true risk of breast cancer and the potential benefits and risks of screening.
在随机对照试验中,乳腺钼靶筛查已显示,在50至69岁女性中,从开始筛查仅五至六年之后,乳腺癌死亡率降低约25%至30%。在40至49岁女性中,试验报告称,从开始筛查七至九年之后,乳腺癌死亡率并未降低;在10至14年之后,乳腺癌死亡率降低了16%。鉴于40至49岁女性的乳腺癌发病率较低,且乳腺钼靶筛查的潜在益处较小且出现延迟,筛查40至49岁女性预防死亡的绝对人数远少于筛查50至69岁女性。由于筛查40至49岁女性的绝对益处较小,且有人担心危害很大,重点应是通过告知这些女性她们患乳腺癌的真实风险以及筛查的潜在益处和风险,帮助她们就乳腺钼靶筛查做出明智决策。